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Background
Systemic Onset Juvenile Idiopathic Arthritis (SoJIA) is
characterized by systemic inflammation besides arthritis.
SoJIA has a broad differential diagnosis. In a minority of
SoJIA patients, it takes time (weeks to months) before
arthritis develops. These cases are challenging for clini-
cians, as is the question how and when to treat these
patients.
Aim
to identify SoJIA patients before the onset of arthritis
and to evaluate treatment with recombinant IL-1RA
(Anakinra) in these ‘suspected SoJIA’ patients.
Methods
We characterized the systemic inflammation in 5 ‘sus-
pected SoJIA’ p a t i e n t sa n dc o m p a r e dt h e mt oo u r
cohort of known SoJIA patients. These 5 patients were
thoroughly checked for alternative diagnoses by exten-
sive microbial analysis (PCR, cultures), radiological eva-
luation (including CT and/or PET scans) and genetic
testing where appropriate. Moreover, bonemarrow aspi-
rates were performed to rule out leukemia and
haemophagocytosis.
Biochemical and immunological parameters of disease
activity (ESR, CRP, Ferritin) as well as newly developed
biomarkers for SoJIA (cytokine profiles (IL-18), MRP’s,
NK cell numbers, phenotype and lytic function) were
assessed at onset of disease and during treatment with
Anakinra.
Results
The 5 ‘suspected SoJIA’ patients were clinically and
immunologically very similar to our cohort of SoJIA
patients (table 1) at time of their diagnosis. We started
Anakinra (dose 2mg/kg/day) in these patients and pro-
spectively followed them for 10 months (5-12) months.
All 5 patients showed beneficial responses to Anakinra,
with fast resolution of inflammation and improved NK
cell function.
Conclusion
Here we show that, making use of recently developed
biomarkers, ‘suspected SoJIA’
patients can be identified very early in their disease-
course, before the development of arthritis. These
patients show a similar beneficial clinical response to
treatment with recombinant IL-1RA as our cohort of
newly diagnosed SoJIA patients. Our data support the
idea of early treatment with recombinant IL-1RA in
(suspected) SoJIA patients.
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Table 1
Disease mark Suspected SoJIA patients
(without arthritis, n=5)
SoJIA cohort
Utrecht (n=15)
Spiking fever 5/5 15/15
Exanthema 2/5 12/15
Arthritis 0/5 15/15
CRP (mg/L) 112±13 209±18
BSE (mm/hr) 128±26 127±34
Ferritin (ug/L) 937±1118 2405±3855
MRP8/14 (U/L) 38490±23077 45185±37260
IL-18 plasma
(ng/L)
3.6±1.7 8.2±9.0
Abs. NK cell
(x10
9/L)
0.096±0.114 0.092±0.132
NK cell function
(% killing)
4.9±3.7 6.5±4.5
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